EPHA2 and pachyonychia congenita: For example, MEDI‐547, the ADC that developed for PC treatment with EphA2 targeting, failed in the clinic due to the severe side effect such as neuropathy.[47] In comparison, ICAM1 is overexpressed at relatively higher levels in PC tumors than EphA2, ≈19 fold as that of the normal controls, while the average of EphA2 is about equal to the normal controls.